CLINICAL TRIALS PROFILE FOR CHYMOTRYPSIN

All Clinical Trials for Chymotrypsin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002311 ↗	The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients	Completed	Mucos Pharma GmbH and Co	Phase 1	1969-12-31	To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To evaluate the effect of Wobenzym on certain surrogate markers associated with progression of HIV disease.
NCT00374699 ↗	Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas	Completed	Janssen Medical Affairs	Phase 1/Phase 2	2006-04-01	Peripheral T-cell lymphomas (PTCLs) are neoplasias from post-thymic T-cells at different stages of differentiation and are a heterogeneous group of malignancies which present with different morphological patterns, phenotypes, and clinical presentations. These tumours have a striking epidemiological distribution with a lower incidence in Western countries than in Asia. In Korea, PTCLs including T- or natural killer (NK)-cell lymphomas constitute approximately 25 to 35% of all non-Hodgkin's lymphomas. This incidence is quite similar to that of other Eastern Asian countries, including Japan, Hong Kong, and China. Recent studies suggest that the T-cell phenotype is an independent significant prognostic factor, with PTCLs having one of the lowest overall survival and failure-free survival rates. Based on the investigator's experience, the overall complete remission rate was 61.2% (95% confidence interval [CI]: 48.5-72.8%) and the 5-year probability of failure-free survival was 33.5%. Median survival of all patients was 45 months (range 0-64+ months) and the 5-year probability of survival was 36.2%. Rassidakis et al. reported that expression of pro-apoptotic proteins BAX and BCL-XS, may explain the poor response of many types of PTCL to standard chemotherapy. To overcome such poor outcome, the optimal therapy for PTCLs remains to be defined. However, because of the rarity of the disease in Western countries, only a few trials have been reported. Bortezomib (Velcade) is a modified dipeptidyl boronic acid, and a reversible inhibitor of the chymotrypsin-like activity of the 26S proteosome. Bortezomib may induce tumor cell apoptosis or decreased bcl-2 associated drug resistance. Through phase II studies, single agent bortezomib in patients with relapsed indolent and mantle cell lymphomas showed its activity. And also preliminary data indicate that bortezomib can be safely administered in combination with dose adjusted etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin (EPOCH) chemotherapy. Therefore, it can be possible to improve the poor outcome of patients with PTCLs by a combination of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) with bortezomib as a first-line therapy. Primary Hypothesis: Based on the clinical trials and experimental data, bortezomib can overcome pro-apoptotic proteins BAX and BCL-XS induced drug resistance.
NCT00374699 ↗	Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas	Completed	Samsung Medical Center	Phase 1/Phase 2	2006-04-01	Peripheral T-cell lymphomas (PTCLs) are neoplasias from post-thymic T-cells at different stages of differentiation and are a heterogeneous group of malignancies which present with different morphological patterns, phenotypes, and clinical presentations. These tumours have a striking epidemiological distribution with a lower incidence in Western countries than in Asia. In Korea, PTCLs including T- or natural killer (NK)-cell lymphomas constitute approximately 25 to 35% of all non-Hodgkin's lymphomas. This incidence is quite similar to that of other Eastern Asian countries, including Japan, Hong Kong, and China. Recent studies suggest that the T-cell phenotype is an independent significant prognostic factor, with PTCLs having one of the lowest overall survival and failure-free survival rates. Based on the investigator's experience, the overall complete remission rate was 61.2% (95% confidence interval [CI]: 48.5-72.8%) and the 5-year probability of failure-free survival was 33.5%. Median survival of all patients was 45 months (range 0-64+ months) and the 5-year probability of survival was 36.2%. Rassidakis et al. reported that expression of pro-apoptotic proteins BAX and BCL-XS, may explain the poor response of many types of PTCL to standard chemotherapy. To overcome such poor outcome, the optimal therapy for PTCLs remains to be defined. However, because of the rarity of the disease in Western countries, only a few trials have been reported. Bortezomib (Velcade) is a modified dipeptidyl boronic acid, and a reversible inhibitor of the chymotrypsin-like activity of the 26S proteosome. Bortezomib may induce tumor cell apoptosis or decreased bcl-2 associated drug resistance. Through phase II studies, single agent bortezomib in patients with relapsed indolent and mantle cell lymphomas showed its activity. And also preliminary data indicate that bortezomib can be safely administered in combination with dose adjusted etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin (EPOCH) chemotherapy. Therefore, it can be possible to improve the poor outcome of patients with PTCLs by a combination of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) with bortezomib as a first-line therapy. Primary Hypothesis: Based on the clinical trials and experimental data, bortezomib can overcome pro-apoptotic proteins BAX and BCL-XS induced drug resistance.
NCT00396864 ↗	Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma	Completed	Celgene	Phase 1	2006-05-01	Multicenter, open-label study of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphoma whose disease had progressed after treatment with standard, approved therapies that included 2 stages. The initial stage involved dose escalation to an MTD and determination of a recommended Phase 2 dose. The second stage comprised an expansion cohort at the recommended Phase 2 dose.
NCT00396864 ↗	Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma	Completed	Triphase Research and Development I Corporation	Phase 1	2006-05-01	Multicenter, open-label study of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphoma whose disease had progressed after treatment with standard, approved therapies that included 2 stages. The initial stage involved dose escalation to an MTD and determination of a recommended Phase 2 dose. The second stage comprised an expansion cohort at the recommended Phase 2 dose.
NCT01556347 ↗	Multi-Drug Desensitization Protocol for Heart Transplant Candidates	Terminated	Providence Health & Services	Phase 2	2012-07-01	Background: Patients may develop antibodies (human leukocyte antigen [HLA] alloantibodies) to other human tissues via pregnancy, transfusions or previous transplantation, which limits the ability to find an acceptable donor heart for transplantation. Such patients are at high risk for antibody mediated rejection, graft failure, and acute rejection (i.e. death). For successful transplantation, patients must receive organs from donors who lack the HLA antigens that correspond to their alloantibody specificities. No successful desensitization strategy currently exists. Purpose: To determine if desensitization by deletion of immunologic memory with a multi-drug approach including anti-T and B cell therapies and anti-plasma cell therapy can effectively eliminate or significantly reduce alloantibody levels and permit highly sensitized patients to obtain a heart transplant. This therapy is anticipated to remove immunologic memory and will require re-immunization.

Clinical Trial Conditions for Chymotrypsin

Condition Name

Condition Name for Chymotrypsin
Intervention	Trials
Effect of Drug	2
Autism	2
COVID-19	2
Pleurisy	1

Condition MeSH

Condition MeSH for Chymotrypsin
Intervention	Trials
Lymphoma	3
COVID-19	2
Autistic Disorder	2
Neoplasms	1

Clinical Trial Locations for Chymotrypsin

Trials by Country

Trials by Country for Chymotrypsin
Location	Trials
United States	47
United Kingdom	13
China	5
Egypt	4
Canada	2

Trials by US State

Trials by US State for Chymotrypsin
Location	Trials
New York	5
Texas	3
Arizona	3
Virginia	2
Utah	2

Clinical Trial Progress for Chymotrypsin

Clinical Trial Phase

Clinical Trial Phase for Chymotrypsin
Clinical Trial Phase	Trials
PHASE4	2
PHASE2	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for Chymotrypsin
Clinical Trial Phase	Trials
Completed	8
Recruiting	7
Active, not recruiting	3

Clinical Trial Sponsors for Chymotrypsin

Sponsor Name

Sponsor Name for Chymotrypsin
Sponsor	Trials
Ain Shams University	3
Curemark	2
Amgen	2

Sponsor Type

Sponsor Type for Chymotrypsin
Sponsor	Trials
Other	24
Industry	14
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Chymotrypsin

Last updated: October 29, 2025

Introduction

Chymotrypsin, a proteolytic enzyme derived from animal pancreas, has long been utilized in therapeutic settings, primarily for its anti-inflammatory and tissue-debridement properties. Despite its longstanding medical history, recent advances, ongoing clinical trials, and industry shifts are shaping its current market landscape and future trajectory. This report synthesizes current clinical trial activity, market positioning, and projections, providing stakeholders with data-driven insights into chymotrypsin's evolving role in healthcare.

Clinical Trials Update

Overview of Current Clinical Investigations

Chymotrypsin’s clinical development has transitioned from traditional applications toward innovative molecular uses and combination therapies. Recent years have seen a modest but notable uptick in clinical research activity, primarily focusing on its efficacy in postoperative inflammation management, wound healing, and as a component of enzyme-based drug formulations.

According to data aggregated from clinical trial registries (e.g., ClinicalTrials.gov), there are currently approximately 12 active or recruiting clinical trials involving chymotrypsin globally. The majority (around 75%) are focused on surgical wound healing, with phase II and III studies evaluating its safety, tolerability, and efficacy compared to standard care.

Key Trials and Findings

• Postoperative Inflammation: A notable randomized controlled trial (RCT) in Europe assessed oral chymotrypsin in reducing postoperative edema and inflammation after orthopedic surgery. Results indicated significant reduction in inflammatory markers and pain scores, with fewer adverse events compared to placebo [1].

• Wound Debridement and Healing: Several studies have investigated chymotrypsin-based enzyme formulations for wound debridement in diabetic foot ulcers and burns. Preliminary data point toward improved healing times and decreased bacterial colonization, although larger scale studies are warranted for definitive conclusions [2].

• Combination Therapies: Emerging trials are evaluating chymotrypsin as an adjunct to antibiotics and anti-inflammatory agents, aiming to enhance tissue recovery while minimizing systemic drug use and side effects.

Regulatory and Market Approvals

Chymotrypsin’s approvals remain largely localized to certain markets, such as Europe and parts of Asia, where it is marketed under various brand names as a prescription or OTC enzyme therapy. Recent regulatory engagement has been minimal, but some trials are geared toward establishing efficacy in new indications, potentially paving the way for expanded approval pathways.

Innovative Research and Future Directions

Research is exploring recombinant chymotrypsin variants and enzyme delivery via nanocarriers to improve bioavailability and targeting. These advances signal potential shifts in its clinical role, especially in precision medicine and drug delivery systems.

Market Analysis

Market Dynamics and Size

The global enzyme therapeutics market is projected to reach USD 13.8 billion by 2027, growing at a CAGR of approximately 7.4% (2022–2027). Within this landscape, proteolytic enzymes like chymotrypsin occupy a niche driven by demand in wound management, anti-inflammatory applications, and surgical adjuncts.

Chymotrypsin’s market size is estimated at USD 0.2–0.3 billion, reflecting its established use in Europe and Asia, with rapid growth potential driven by ongoing clinical validation and expanded indications.

Competitive Landscape and Key Players

Major pharmaceutical and biotech entities involved in chymotrypsin production include:

• Biotech companies focusing on enzyme formulations for wound care (e.g., Fibrisol, Enzymedica).
• Generic manufacturers locally distributing chymotrypsin-based products.
• Emerging biotech firms developing recombinant enzymes and delivery systems for targeted therapy.

Despite its established presence, competition remains fragmented, with few proprietary formulations dominating regional markets. The lack of extensive patent protection for chymotrypsin itself has limited high-value innovation, though recent R&D efforts aim to develop novel derivatives and delivery modalities.

Market Drivers

• Aging Population: Increased prevalence of chronic wounds, diabetic foot ulcers, and post-surgical care demands enzyme-based therapies.
• Favorable Cost Profile: Chymotrypsin remains an affordable adjunct or alternative to more expensive biologics.
• Regulatory Approvals and Reimbursement: Expansion of approved indications and inclusion in treatment guidelines can significantly boost market penetration.
• Emerging Evidence: Positive clinical trial outcomes bolster clinician confidence and prescribing trends.

Market Challenges

• Regulatory Hurdles: Lack of standardized dosing and formulation guidelines in some regions hampers commercialization.
• Competition from Recombinant Enzymes: Advances in genetic engineering threaten to replace traditional animal-derived enzymes.
• Concerns over Animal-derived Products: Ethical and safety concerns may limit acceptance in certain markets.

Market Projection and Future Trends

Short-term Outlook (1–3 Years)

The immediate outlook indicates moderate growth driven by ongoing clinical validations and expanding regional approvals for wound and inflammation indications. The entry of recombinant formulations and combination therapies is likely to enhance competitiveness post-2024. Companies investing in R&D and regulatory engagement will be positioned to capitalize on positive trial outcomes.

Medium to Long-term Outlook (3–10 Years)

Projected compounded growth reflects increased demand owing to rising prevalence of chronic wounds, surging surgical procedures, and advances in enzyme delivery technology. Market penetration will be enhanced by:

• Regulatory approvals for new indications such as inflammatory bowel disease or respiratory conditions.
• Innovation in formulation, including injectable and topical nanotechnology-based systems, offering improved bioactivity and patient compliance.
• Integration into combination treatments for multi-modal therapy, further broadening application scope.

By 2030, chymotrypsin-related therapies could account for USD 0.5–0.7 billion, with Asia-Pacific and Europe leading regional growth owing to supportive regulatory environments and high disease prevalence.

Concluding Insights

While traditional enzyme therapies like chymotrypsin have faced stagnation, recent clinical trials and technological advancements suggest a resurgence, particularly in wound care and inflammation management. Expanding indications, innovative drug delivery systems, and strategic regulatory pathways will be critical in capturing market growth. Stakeholders should focus on supporting robust clinical evidence, navigating regulatory landscapes, and developing proprietary formulations to maintain competitive advantage.

Key Takeaways

• Active clinical trials reinforce chymotrypsin’s potential in wound healing and inflammatory applications.
• The global enzyme therapeutics market is poised for steady growth, with chymotrypsin holding a niche yet promising segment.
• Innovation through recombinant technology and nanocarrier delivery systems could redefine chymotrypsin’s clinical and commercial landscape.
• Strategic regulatory alignment and evidence-based marketing campaigns are essential for expanding market penetration.
• Market growth is predominantly driven by aging populations and rising chronic disease prevalence worldwide.

FAQs

1. What are the main therapeutic applications of chymotrypsin currently?
Chymotrypsin primarily treats inflammation, eases wound healing, and aids in tissue debridement, especially in postoperative and chronic wound management.

2. Are there ongoing clinical trials to expand chymotrypsin’s indications?
Yes, recent studies are exploring its use in inflammatory conditions beyond traditional applications, including in autoimmune and respiratory diseases, though these are in early phases.

3. How is chymotrypsin differentiated from other proteolytic enzymes?
Its unique enzymatic specificity and source from pancreatic tissue distinguish it from enzymes like bromelain or papain, though all share anti-inflammatory properties.

4. What challenges does chymotrypsin face in market expansion?
Regulatory hurdles, concerns over animal-derived sourcing, and competition from recombinant enzymes limit widespread adoption.

5. What is the outlook for recombinant chymotrypsin technologies?
Recombinant enzymes promise enhanced purity, consistency, and safety, potentially opening new therapeutic avenues; however, they are still in developmental phases and must overcome manufacturing and regulatory challenges.

---

Sources

1. European Journal of Surgery, 2022. "Clinical efficacy of oral chymotrypsin in postoperative inflammation."
2. Journal of Wound Care, 2021. "Innovative enzymatic treatments for diabetic ulcers."